Downregulation of miR-342 is associated with tamoxifen resistant breast tumors

BACKGROUND: Tumor resistance to the selective estrogen receptor modulator tamoxifen remains a serious clinical problem especially in patients with tumors that also overexpress HER2. We have recently demonstrated that the clinically important isoform of HER2, HERΔ16, promotes therapeutically refracto...

Descripción completa

Detalles Bibliográficos
Autores principales: Cittelly, Diana M, Das, Partha M, Spoelstra, Nicole S, Edgerton, Susan M, Richer, Jennifer K, Thor, Ann D, Jones, Frank E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024251/
https://www.ncbi.nlm.nih.gov/pubmed/21172025
http://dx.doi.org/10.1186/1476-4598-9-317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024251/
https://www.ncbi.nlm.nih.gov/pubmed/21172025
http://dx.doi.org/10.1186/1476-4598-9-317

Ejemplares similares